Insider · CIK 0001331852
Joseph S Zakrzewski
Files at ANTX (AN2 Therapeutics, Inc.). First filing Nov 20, 2024, latest Nov 27, 2024.
In brief
Joseph S Zakrzewski files SEC Form 4 as director at ANTX (AN2 Therapeutics, Inc.). Since Nov 20, 2024, Joseph S Zakrzewski has reported 2 open-market buys worth $28k and 0 open-market sells worth $0, the latest filed on Nov 27, 2024.
A track record needs three past buys with six months of prices behind them; Joseph S Zakrzewski has 0, so none is measured yet.
The newest scored trade: bought $2,800 of ANTX on Nov 27, 2024, filed Nov 27, 2024, scored 35 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANTX: AN2 Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | AN2 Therapeutics, Inc. | $2,800 2,000 shares | +2% | - | |
| 41Moderate | AN2 Therapeutics, Inc. | $25k 25,000 shares | +25% | - |
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ANTX AN2 Therapeutics, Inc. | GGift Common Stockindirect: See footnote | -405,880 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +99,999 | - | - | 99,999 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -99,999 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,362 | - | - | 10,362 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -10,362 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +23,742 | - | - | 23,742 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -23,742 | - | - | 0 | Mar 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Feb 23, 2026 |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| Apr 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +10,523 | $0.00 | $0 | 145,538 | Apr 11, 2025 |
| Dec 19, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +9,816 | $0.00 | $0 | 135,015 | Dec 23, 2024 |
| Nov 27, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stock | +2,000 | $1.40 | $2,800 | 125,199 | Nov 27, 2024 |
| Nov 18, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stock | +20,000 | $1.00 | $20k | 118,199 | Nov 20, 2024 |
| Nov 19, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stock | +5,000 | $1.01 | $5,050 | 123,199 | Nov 20, 2024 |
Questions about Joseph S Zakrzewski
Answered from the filings on this page, as of the latest one.
Is Joseph S Zakrzewski buying or selling?
Not in the last 12 months. Joseph S Zakrzewski's latest open-market trade on SEC Form 4 was bought $2,800 of ANTX on Nov 27, 2024.
How did Joseph S Zakrzewski's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joseph S Zakrzewski has 0.
Where does Joseph S Zakrzewski file Form 4?
Joseph S Zakrzewski has filed Form 4 at ANTX (AN2 Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.